CN Patent

CN109464445A — 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合

Assigned to Wyeth LLC · Expires 2019-03-15 · 7y expired

What this patent protects

提供了治疗肿瘤的4‑苯胺基‑3‑氰基喹啉化合物(例如，HKI‑272、SKI‑606、EKB‑569)和卡培他滨化合物的组合。也描述了使用该组合并任选与其他抗肿瘤剂或免疫调节剂组合，治疗肿瘤包括乳腺癌(包括转移性乳腺癌)和肺癌的用药方案、试剂盒和方法。

USPTO Abstract

提供了治疗肿瘤的4‑苯胺基‑3‑氰基喹啉化合物(例如，HKI‑272、SKI‑606、EKB‑569)和卡培他滨化合物的组合。也描述了使用该组合并任选与其他抗肿瘤剂或免疫调节剂组合，治疗肿瘤包括乳腺癌(包括转移性乳腺癌)和肺癌的用药方案、试剂盒和方法。

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN109464445A
Jurisdiction: CN
Classification: —
Expires: 2019-03-15
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.